期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 97, 期 1, 页码 22-28出版社
WILEY
DOI: 10.1002/cpt.6
关键词
-
资金
- NIDDK NIH HHS [P30 DK097948, R01 DK055812, P01 DK091222, R01 DK042191] Funding Source: Medline
Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammatory disease of the intestine that includes both Crohn's disease and ulcerative colitis, and afflicts nearly 1 million people throughout North America. As our understanding of IBD pathogenesis grows, several new therapies have been developed that use monoclonal antibodies to specifically target key mediators and biological pathways implicated in IBD immune dysfunction. One important pathway involves leukocyte trafficking and infiltration into the affected intestinal tissues. This review provides a summary of the different therapies that have been developed to inhibit leukocyte trafficking to the inflamed gut, and evaluates the relative safety and efficacy of these novel drugs within the context of existing medical therapies for IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据